The federal cannabis rescheduling process faced an unexpected administrative delay this week. DEA Chief Administrative Law Judge Derek C. Julius paused the upcoming hearings to evaluate whether a recent Government Accountability Office report should be formally admitted into the evidentiary record.
The federal watchdog report severely criticized both the Drug Enforcement Administration and the Food and Drug Administration for failing to maintain adequate, standardized procedures when evaluating and scheduling controlled substances. According to the GAO findings, neither agency possesses documented protocols for properly conducting scientific and medical evaluations required during the scheduling review. This procedural gap directly questions the foundational methodology behind the current move to transfer cannabis from Schedule I to Schedule III.
Stakeholders across the supply chain—from multi-state operators to independent brand manufacturers—must monitor these proceedings closely. While a Schedule III designation would eliminate the burdensome tax penalties imposed by Section 280E and normalize interstate banking relations, judicial pauses introduce uncertainty regarding the timeline. If the administrative hearings are forced to incorporate new compliance frameworks or rewrite evaluation standards, the final decision could face prolonged delays.
Dispensary owners and brand managers should maintain standard operating procedures under current federal guidelines while preparing contingency plans for shifting regulatory realities.